Business Wire34m
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX ...
Business Wire34m
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy
PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...
Business Wire34m
PHAXIAM fait le point sur le déploiement de sa stratégie permettant de maximiser le potentiel de développement de la phagothérapie
Regulatory News: PHAXIAM Therapeutics (Euronext : PHXM - FR0011471135), ci-après « la Société » ou « PHAXIAM », société biopharmaceutique spécialisée ...
Business Wire34m
BrightHeart Unveils Breakthrough AI Results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, Revolutionizing Prenatal Care
BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies d ...